跳至主要内容
临床试验/NCT04699591
NCT04699591招募中不适用

Compassionate Use of Domperidone for Refractory Gastroparesis

Jose Cocjin1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2013年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
20
试验地点
1
主要终点
Change in disease severity

研究概览

简要总结

The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.

详细描述

The following will need to be completed before the investigational treatment can begin:

  • Your medical history will be reviewed to make sure domperidone is a safe option for treatment
  • You will have a physical examination, including heart and breathing rates, blood pressure, height, weight, and an ECG. An ECG measures the electrical activity of the heart over a period of time. This is a non-invasive procedure and involves attaching sticky pads to your chest and recording your body's electrical activity on a machine. The study doctor/nurse will explain this in more detail to you.
  • You will have up to 3 teaspoons of blood drawn through a needle in the arm to make sure it is safe for you to receive domperidone.
  • You will have a pregnancy test if you are female.

If your tests results are acceptable, the following will happen to you:

  • You will take domperidone 4 times per day. The dose will be calculated by your doctor according to your weight.
  • Every two months for the first year, you will have a physical examination, including heart and breathing rates, blood pressure, height, weight, up to 3 teaspoons of blood drawn through a needle in your arm to measure blood levels, and an ECG.
  • You will also have an ECG anytime there is an increase in the amount of domperidone you are taking.
  • After the first year, if you are benefitting from taking domperidone you will have a physical examination, blood draw and ECG every six months until you stop taking domperidone.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
12 Years 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female
  • Age 12 - 21
  • Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.
  • Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.
  • Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:
  • increased prolactin levels
  • extrapyramidal side effects
  • breast changes
  • Cardiac arrhythmias including QT prolongation
  • There is a potential for increased risk of adverse events with the drugs and herbal supplements listed in the addendum (See Addendum on pages 24 and 25)
  • The coordinator/investigator will have a discussion with the family about the use of any of the medications and herbal supplements listed in the addendum to make sure they understand the increased risk of their use and the need to contact the investigators prior to using any of the listed medications and herbal supplements.

排除标准

  • History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.
  • Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged Tc (QTc> 450 milliseconds for males, QTc>470 milliseconds for females).
  • Clinically significant electrolyte disorders.
  • Gastrointestinal hemorrhage or obstruction
  • Presence of a prolactinoma (prolactin-releasing pituitary tumor).
  • Pregnant or breast feeding female
  • Known allergy to domperidone

研究组 & 干预措施

Overall Study

Other

Receive domperidone 4 times a day, weight-dependent dose

干预措施: Domperidone (Drug)

结局指标

主要结局

Change in disease severity

时间窗: Up to 1 year

refractory gastroparesis or GERD(Gastroesophageal Reflux Disease)

次要结局

未报告次要终点

研究者

发起方
Jose Cocjin
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jose Cocjin

MD, Physician

Children's Mercy Hospital Kansas City

研究点 (1)

Loading locations...

相似试验